• Artios bags $84M to trial next-generation DNA damage response drugs fiercebiotech
    August 13, 2018
    Artios Pharma has raised $84 million (£65 million) to take DNA damage response (DDR) programs to clinical proof of concept. The series B round sees more big-name investors give cash to researchers whose earlier work on PARP inhibitor Lynparza put DDR on t
PharmaSources Customer Service